ClinicalTrials.gg
Enrolling by invitationNCT05739071Updated Oct 5, 2026

JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer

An interventional study of JING SI HERBAL TEA and Placebo in Lower Urinary Tract Symptoms, Intravenous Drug Usage and Bladder Cancer, sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Lower Urinary Tract Symptoms with a site in Taiwan — 4 open to participants now, 4 under way, none of them phase 3. Lower Urinary Tract Symptoms · Taiwan.

Planned enrollment
8th of 15
100 · median 100
Started
2023
with 2 others
No phase
8 of 29
2 open now
Registered
25th of 29
by date

Among the 29 studies in Lower Urinary Tract Symptoms with a site in Taiwan, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 25th registered.

Lower Urinary Tract Symptoms

417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

Browse Lower Urinary Tract Symptoms studies →

Open to participants now

4 of the 29 studies in Lower Urinary Tract Symptoms with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Lower Urinary Tract Symptoms with a site in Taiwan, or all of them as a file.
02

Study summary

To identify the effects of JING SI HERBAL TEA in the treatment of lower urinary tract symptoms after intravesical therapy in patients with bladder cancer.

Read the detailed description

The patients with bladder cancer usually required trans urethral resection of bladder tumor (TUR-BT). Post-operative intravesical installation therapy is standard therapy. However, new onset lower urinary tract symptoms often occurred after these installation therapies. JING SI HERBAL TEA is a food contain of many herbal extracts with anti-inflammation effects. The current study is to find out the effects of JING SI HERBAL TEA in the treatment of this condition.

The patients will be divided into two groups by randomly assigned (estimated case number=100, experimental: control = 1: 1). The first group will receive two sachets of JING SI HERBAL TEA a day (one in the morning and one in the evening). The second group will receive two sachets of placebo a day (same way as group 1). The therapy will be three days after each intravesical installation therapies.

The outcome evaluations will use the American Urological Association Symptom Index and 12-Item Short Form Survey (SF-12). The baseline symptoms will be recorded before the first intravesical therapy. Patients will be asked to fill out the questionnaire every week (the same time for the next installation). Every other standard cancer therapies will not be will not be affected.

03

Conditions studied

  • Lower Urinary Tract Symptoms
  • Intravenous Drug Usage
  • Bladder Cancer
  • Herbal Interaction

Keywords

  • Intravesical installaion
  • Bladder cancer
  • Lower urinary tract symptoms
  • JING SI HERBAL TEA
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis bladder cancer
  • Under intravesical installation therapy

Exclusion criteria

Exclusion Criteria:

  • Patients under 20 years old or greater than 100 years old
  • Women with pregnancy or breastfeeding plans
  • Bladder cancer are being treated in another hospital
  • Had admitted due to other disease in the past 3 months
  • Unable to understand the questionnaire
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Experimental (group 1)

    This group will receive two sachets of JING SI HERBAL TEA a day (one in the morning and one in the evening).

    Dietary Supplement: JING SI HERBAL TEA

  • Placebo comparator
    Control (group 2)

    This group will receive two sachets of placebo a day (same way as group 1).

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementJING SI HERBAL TEA

    JING SI HERBAL TEA is a food, contain with herbal extracts

  • Dietary supplementPlacebo

    Placebo will have the same appearance as JING SI HERBAL TEA

06

What researchers measure

Primary outcomes

  1. Urinary symptoms

    Change from baseline score at the following time will be recorded. The American urological association symptom index is a 7-item self report measure to assess the urinary symptoms. The score range from 0 to 35, the higher the severity.

    Time frame: The outcome evaluation will be at the following time points: 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks and 6 weeks

Secondary outcomes

  1. Life quality

    Change from baseline score at the following time will be recorded. The 12-item shor form survey is a general health questionaire for life quality evaluation. The higher the value obtained, the more significant the impact on life.

    Time frame: The outcome evaluation will be at the following time points: 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks and 6 weeks

07

Study locations

1 site
  • Buddhist Tzu Chi General Hospital, Taipei branch
    Taipei, Taiwan 231, Taiwan
08

References and documents

Individual participant data

Plan to share: No — The JING SI HERBAL TEA and Placebo are provided by the Tzu Chi Medical Foundation. We can not determining whether there are sufficient materials to provide the other participants

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 98 non-industry interventional studies with no phase under Lower Urinary Tract Symptoms, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 46 months is above that.

Counting every sponsor, half of 119 studies reached it within 27 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2023
First posted
Feb 22, 2023
StartActual
Feb 22, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05739071
Lead sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Feb 22, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Shu-Yu Wu, bachelor
study director · Taichung Tzu Chi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jing Si Herbal Tea

Start the discussion